Ergotamine Derivatives: Uses, Mechanisms, and Global Trade Dynamics
What are the primary uses of ergotamine derivatives. How do these compounds work in treating migraines and cluster headaches. What are the major global trade patterns for ergot alkaloids and their derivatives.
Pharmacological Properties of Ergotamine Derivatives
Ergotamine derivatives are a class of compounds derived from ergot alkaloids, naturally occurring substances produced by fungi. These derivatives have significant pharmacological effects, particularly in treating vascular headaches like migraines and cluster headaches.
Key Ergotamine Derivatives
- Dihydroergotamine
- Ergotamine
- Dihydroergotoxine
Dihydroergotamine and ergotamine are the most clinically relevant derivatives used in headache treatment. How do these compounds exert their therapeutic effects?
Mechanism of Action
Ergotamine derivatives act as agonists at several receptors, primarily:
- Serotonin (5-HT) receptors: 5-HT1B, 5-HT1D, 5-HT1F
- Adrenergic receptors: Alpha-1, Alpha-2
- Dopamine receptors: D2, D3, D4
This diverse receptor profile contributes to their complex pharmacological effects. The primary therapeutic mechanism involves vasoconstriction of cranial blood vessels and inhibition of neurogenic inflammation, which helps alleviate migraine symptoms.
Therapeutic Applications of Ergotamine Derivatives
Ergotamine derivatives have found their niche in treating specific types of headaches. What are their primary indications?
Migraine Treatment
Both dihydroergotamine and ergotamine are used in the acute treatment of migraine headaches. They are particularly effective for:
- Migraines with or without aura
- Prolonged or refractory migraine attacks
- Patients who do not respond well to triptans
Cluster Headache Management
Ergotamine derivatives, especially dihydroergotamine, have shown efficacy in managing cluster headaches. These severe, unilateral headaches often respond well to the potent vasoconstrictor effects of these compounds.
Pharmacokinetics and Administration Routes
Understanding the pharmacokinetics of ergotamine derivatives is crucial for their effective use. How are these drugs typically administered?
Administration Routes
- Oral tablets (ergotamine)
- Sublingual tablets (ergotamine)
- Nasal spray (dihydroergotamine)
- Intramuscular or subcutaneous injection (dihydroergotamine)
- Intravenous infusion (dihydroergotamine, in hospital settings)
The route of administration significantly affects the drug’s bioavailability and onset of action. Parenteral routes generally provide faster relief but may require medical supervision.
Metabolism and Elimination
Ergotamine derivatives are primarily metabolized by the liver, specifically by the cytochrome P450 3A4 enzyme. This metabolic pathway has important implications for drug interactions and dosing considerations in patients with hepatic impairment.
Side Effects and Safety Considerations
While effective, ergotamine derivatives are associated with a range of potential side effects. What are the most common adverse reactions?
Common Side Effects
- Nausea and vomiting
- Dizziness
- Paresthesia
- Muscle pain
- Chest tightness
Serious Adverse Effects
Long-term or excessive use of ergotamine derivatives can lead to more severe complications:
- Ergotism: a serious condition characterized by vasoconstriction and ischemia
- Fibrosis of cardiac valves or retroperitoneal tissues
- Rebound headaches (medication overuse headache)
These risks necessitate careful patient selection and monitoring when prescribing ergotamine derivatives.
Drug Interactions and Contraindications
The complex pharmacology of ergotamine derivatives leads to numerous potential drug interactions. Which medications should be avoided when using these compounds?
Major Drug Interactions
- CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): can dramatically increase ergotamine levels
- Triptans: risk of additive vasoconstrictive effects
- Beta-blockers: may enhance peripheral vasoconstriction
- Nicotine: increased risk of vasospasm
Contraindications
Ergotamine derivatives are contraindicated in several conditions:
- Peripheral vascular disease
- Coronary artery disease
- Uncontrolled hypertension
- Pregnancy and breastfeeding
- Severe renal or hepatic impairment
These contraindications highlight the importance of thorough patient evaluation before prescribing ergotamine derivatives.
Global Trade Dynamics of Ergot Alkaloids and Derivatives
The international trade of ergot alkaloids and their derivatives represents a niche but significant market in the pharmaceutical industry. What are the key trends and players in this global trade?
Major Exporting Countries
In 2020, the top exporters of ergot alkaloids and derivatives (excluding ergometrine, ergotamine, and lysergic acid) were:
- Czech Republic: US$44.7 million
- Italy: US$27.1 million
- India: US$3.71 million
These countries have established themselves as key players in the production and export of these specialized pharmaceutical compounds.
Primary Importing Nations
The main importers of ergot alkaloids and derivatives in 2020 were:
- China: US$20.3 million
- Japan: US$10.6 million
- Romania: US$6.9 million
This import pattern reflects the global distribution of pharmaceutical manufacturing and research facilities utilizing these compounds.
Mexico’s Trade Profile
Mexico’s trade in ergot alkaloids and derivatives shows interesting patterns:
- In 2022, Ciudad de México was the leading state for international purchases, totaling US$110,000
- Major sources of imports in 2022 included Czech Republic, India, Italy, Germany, and France
- A significant trade deficit was observed, with imports far exceeding exports
This trade profile suggests that Mexico relies heavily on imports to meet its domestic needs for these compounds.
Research and Development in Ergotamine Derivatives
Despite their long history of use, ergotamine derivatives continue to be the subject of ongoing research. What are some current areas of investigation?
Novel Formulations
Researchers are exploring new formulations to improve the bioavailability and reduce side effects of ergotamine derivatives. Some promising approaches include:
- Nanoparticle-based delivery systems
- Transdermal patches
- Mucoadhesive buccal films
Combination Therapies
Combining ergotamine derivatives with other classes of medications is an active area of research. Potential combinations include:
- Ergotamine derivatives with NSAIDs for enhanced pain relief
- Combinations with antiemetics to reduce nausea and improve tolerance
These research directions aim to enhance the efficacy and tolerability of ergotamine derivatives in headache management.
Future Perspectives and Challenges
As our understanding of headache pathophysiology evolves, what does the future hold for ergotamine derivatives?
Emerging Competitors
The development of new classes of migraine medications poses challenges to the continued use of ergotamine derivatives:
- CGRP antagonists offer a novel approach to migraine prevention and treatment
- Advanced formulations of triptans may provide safer alternatives for acute treatment
Personalized Medicine Approaches
The future of headache treatment may involve more personalized approaches:
- Genetic profiling to predict response to ergotamine derivatives
- Biomarker-guided selection of optimal treatment strategies
These advancements could help optimize the use of ergotamine derivatives in specific patient populations.
In conclusion, ergotamine derivatives remain important tools in the management of migraines and cluster headaches. Their complex pharmacology, while challenging, provides unique therapeutic benefits. Ongoing research and global trade dynamics continue to shape the role of these compounds in modern medicine. As we advance our understanding of headache disorders and develop new treatment modalities, the precise niche for ergotamine derivatives in clinical practice will likely continue to evolve.
Ergotamine Derivative | DrugBank Online
All categories
- Name
- Ergotamine Derivative
- Accession Number
- DBCAT003327
- Description
Not Available
- Drugs
Drug Drug Description Dihydroergotamine An ergot alkaloid used in the acute treatment of migraine headache and cluster headache. Ergotamine An alpha-1 selective adrenergic agonist vasoconstrictor used to treat migraines with or without aura and cluster headaches. Dihydroergotoxine Not Annotated - Drugs & Drug Targets
Drug Target Type Dihydroergotamine 5-hydroxytryptamine receptor 1D target Dihydroergotamine 5-hydroxytryptamine receptor 1B target Dihydroergotamine Cytochrome P450 3A4 enzyme Dihydroergotamine Alpha-2A adrenergic receptor target Dihydroergotamine 5-hydroxytryptamine receptor 2B target Dihydroergotamine P-glycoprotein 1 transporter Dihydroergotamine 5-hydroxytryptamine receptor 1A target Dihydroergotamine 5-hydroxytryptamine receptor 1E target Dihydroergotamine 5-hydroxytryptamine receptor 2A target Dihydroergotamine 5-hydroxytryptamine receptor 2C target Dihydroergotamine Alpha-1 adrenergic receptors target Dihydroergotamine Alpha-2 adrenergic receptors target Dihydroergotamine Dopamine D2 receptor target Dihydroergotamine Dopamine D3 receptor target Dihydroergotamine Dopamine D4 receptor target Dihydroergotamine 5-hydroxytryptamine receptor 1F target Dihydroergotamine 5-hydroxytryptamine receptor 4 target Dihydroergotamine Beta-3 adrenergic receptor target Ergotamine Alpha-1A adrenergic receptor target Ergotamine 5-hydroxytryptamine receptor 1D target Ergotamine 5-hydroxytryptamine receptor 1B target Ergotamine 5-hydroxytryptamine receptor 2A target Ergotamine Alpha-2A adrenergic receptor target Ergotamine Dopamine D2 receptor target Ergotamine Cytochrome P450 3A4 enzyme Ergotamine Alpha-1B adrenergic receptor target Ergotamine Alpha-1D adrenergic receptor target Ergotamine P-glycoprotein 1 transporter Ergotamine D(1) dopamine receptor target Ergotamine 5-hydroxytryptamine receptor 1A target Ergotamine 5-hydroxytryptamine receptor 1F target Ergotamine 5-hydroxytryptamine receptor 2C target Ergotamine 5-hydroxytryptamine receptor 2B target Ergotamine Alpha-2C adrenergic receptor target
Ergot Alkaloids of Rye and its Derivatives; Salts Thereof (Excl.
Ergometrine, Ergotamine, Lysergic Acid and Salts Thereof): Commercial exchange, international purchases and sales, market and specialization
About
#permalink to section
The states with the most international purchases in 2022 were Ciudad de México (US$110k).
The main commercial origins of Ergot Alkaloids of Rye and its Derivatives; Salts Thereof (Excl. Ergometrine, Ergotamine, Lysergic Acid and Salts Thereof) in 2022 were Czech Republic (US$33.5k), India (US$30k), Italy (US$29k), Germany (US$16.6k), and France (US$1k).
In the global context, the main exporting countries of Ergot Alkaloids of Rye and its Derivatives; Salts Thereof (Excl. Ergometrine, Ergotamine, Lysergic Acid and Salts Thereof) in 2020 were Czech Republic (US$44.7M), Italy (US$27.1M), and India (US$3.71M). In the same year, the main importing countries of Ergot Alkaloids of Rye and its Derivatives; Salts Thereof (Excl. Ergometrine, Ergotamine, Lysergic Acid and Salts Thereof) were China (US$20.
3M), Japan (US$10.6M), and Romania (US$6.9M).
Trade Balance of Mexico
#permalink to section
Net Trade Balance
#permalink to section
Year20222021202020192018201720162015201420132012201120102009200820072006
The visualizations show the net balance of Ergot Alkaloids of Rye and its Derivatives; Salts Thereof (Excl. Ergometrine, Ergotamine, Lysergic Acid and Salts Thereof) at the level of states and countries. Colors more similar to blue, indicate that the territory presented a higher level of international sales. Colors more similar to red, indicate that the territory presented a higher level of international purchases.
Net International Trade
#permalink to section
June, 2020: US$5.74M, International Purchases
In June 2020, international sales of Ergot Alkaloids of Rye and its Derivatives; Salts Thereof (Excl. Ergometrine, Ergotamine, Lysergic Acid and Salts Thereof) were US$0, while international purchases reached US$5.
74M. The above results in a trade balance of -US$5.74M.
Exchange by Territory
#permalink to section
International Purchases
#permalink to section
Year20222021202020192018201720162015201420132012201120102009200820072006
In 2022, the states with the highest international in Ergot Alkaloids of Rye and its Derivatives; Salts Thereof (Excl. Ergometrine, Ergotamine, Lysergic Acid and Salts Thereof) were Ciudad de México (US$110k).
The countries with the most international sales to Mexico in 2022 were Czech Republic (US$33.5k), India (US$30k), Italy (US$29k), Germany (US$16.6k), and France (US$1k).
Specialization
#permalink to section
Specialization by State
#permalink to section
The RCA-Complexity diagram compares the Revelead Comparative Advantages of states in Ergot Alkaloids of Rye and its Derivatives; Salts Thereof (Excl. Ergometrine, Ergotamine, Lysergic Acid and Salts Thereof) and the Economic Complexity Index of each state.
RCA values greater than 1 indicate that the state has comparative advantages in Ergot Alkaloids of Rye and its Derivatives; Salts Thereof (Excl. Ergometrine, Ergotamine, Lysergic Acid and Salts Thereof). On the other hand, high levels of complexity (ECI) are associated with higher levels of income, potential for economic growth, lower income inequality and lower emissions.
Global Market
#permalink to section
Origins and Trade Destinations
#permalink to section
20202019201820172016201520142013
The visualizations show the global market for Ergot Alkaloids of Rye and its Derivatives; Salts Thereof (Excl. Ergometrine, Ergotamine, Lysergic Acid and Salts Thereof). In both charts, Mexico stands out in order to identify its participation in the export and import market.
In 2020, the main exporting countries of Ergot Alkaloids of Rye and its Derivatives; Salts Thereof (Excl.
Ergometrine, Ergotamine, Lysergic Acid and Salts Thereof) were Czech Republic (US$44.7M), Italy (US$27.1M), and India (US$3.71M). In the same year, the main importing countries for Ergot Alkaloids of Rye and its Derivatives; Salts Thereof (Excl. Ergometrine, Ergotamine, Lysergic Acid and Salts Thereof) were China (US$20.3M), Japan (US$10.6M), and Romania (US$6.9M).
Consequences of misuse of painkillers
Pain medications (non-steroidal anti-inflammatory drugs – NSAIDs, ergotamine derivatives, analgesics) are the most popular and widely used over-the-counter drugs.
Pain medications (non-steroidal anti-inflammatory drugs – NSAIDs, ergotamine derivatives, analgesics) are the most popular and widely used OTC drugs. At the same time, headaches (cephalgia) are very often the cause of their use. Most often it is the so-called tension headache and migraine.
The possibility of buying a drug without a doctor’s prescription in Ukraine leads to the fact that many people decide on their own which drug, at what dose and with what frequency to take.
And therein lies the danger, since for each drug there are certain contraindications and restrictions for use.
First, the uncontrolled use of analgesics and NSAIDs often leads to the development of various side effects, including changes in blood composition, gastrointestinal bleeding, erosions and ulcers in the digestive tract.
And secondly, irrational (too frequent or exceeding the recommended dosage) use of painkillers for cephalalgia, including migraine, often causes the so-called drug-induced or abuse headache. Most often, such a headache occurs in chronic migraine as a result of chronic abuse of drugs for the treatment of attacks of cephalalgia. The development of overuse headache is indicated by the use of painkillers more than 2-3 times a week (10 times a month) for 3 or more months. At the same time, the severity of headache attacks and the frequency of their occurrence can progress against the background of excessive drug intake.
Interestingly, analgesic-associated headache occurs only in patients with primary headache (80% of overbusy headache patients are migraine patients) and never develops as a result of taking the same drugs, but according to different indications (for example, osteoarthritis).
Theoretically, too frequent use of any migraine medications, including analgesics, NSAIDs, ergotamine derivatives, opioids, triptans, can lead to the development of “abuses”. However, since the fact of abuse (i.e., excessive frequency of use) of the drug is of greatest importance here, this problem most often occurs when taking NSAIDs and analgesics, given their greater availability and less effectiveness in moderate and severe forms of migraine. As for the mechanisms of development of abusus cephalgia, it is assumed that it is based on changes in the parts of the brain responsible for conducting pain impulses that arise as a result of regular use of headache medications.
Diagnosis of overuse headache is not difficult – it is enough to analyze the entries in the headache diary of a patient who has addressed a doctor with complaints of progression of migraine or other primary headache, in which the time of onset of headache attacks and the number of pain medications taken for at least 3 months.
The superimposition of drug-induced headache on migraine symptoms significantly worsens the patient’s condition and requires proper treatment, the effectiveness of which depends on the patience and discipline of the patient. First of all, the doctor studies the treatment regimen, finds and cancels the “guilty” drug. Usually the complete withdrawal of such pain medication is sufficient intervention, however, in severe cases, inpatient treatment with antidepressants and detoxification therapy may be required. At the second stage, a correction of the migraine treatment regimen is carried out in order to effectively prevent attacks and most sparing pain relief in the event of the development of cephalalgia. Treatment regimens with alternating periods of frequent use of the drug and relatively long periods without treatment are preferred, since the regular use of painkillers is a major risk factor for the development of abuse headaches. A necessary condition for the effective treatment of “abuses” is the refusal to take the analgesic that caused the development of abuses headache, since any therapy will be much less effective if the patient continues to use such a drug on a regular basis.
Prevention of the development of drug-induced headaches in people with migraine and other primary cephalalgias consists in refusing self-medication and strictly following the doctor’s recommendations. In particular, it is of great importance to abandon the uncontrolled increase in the doses and frequency of taking NSAIDs and analgesics, in case of their ineffectiveness, in favor of switching to triptans.
Sources:
- https://www.webmd.com/pain-management/pain-medication-side-effects#1
- https://www.healthline.com/health/opioids-and-related-disorders#symptoms
to the list of articlesFind a doctor
TN VED code 2939620000. Online service
TN VED
Online service
Ergotamine (INN) and its salts
HS position
|
Products of the chemical and related industries (Chapters 28-38)
.. Position OKPD 2
|
Customs fees
Import
| Basic rate of customs duty | 3% sol.  |